Efzimfotase alfa is an investigational enzyme replacement therapy designed to reduce injection volume
The investigational new drug application with FDA was actually for NEOK002, an EGFR/MUC1-targeting antibody-drug conjugate aimed at solid tumors
The decision is based on the phase 3 DESTINY-Breast11 trial
The SCOUT-HCM trial hit its primary endpoint, showing a clinically meaningful and statistically significant reduction in Valsalva left ventricular outflow tract
Price of the starting dose of Ozempic and Wegovy reduced by 36% and 48% respectively
The findings were presented as a late-breaking study at the 2026 American Academy of Dermatology
Otsuka will pay $700 million to Transcend shareholders at closing, with an additional $525 million in contingent payments tied to future sales milestones
The milestone moves the company closer to its previously announced $120 million US expansion, with groundbreaking slated for late 2026
The collaboration will see HNL Lab Medicine deploy Ibex’s cutting-edge AI solution, Ibex Prostate, for biopsies and transurethral resection of the prostate (TURP), boosting both diagnostic accuracy and workflow efficiency
Subscribe To Our Newsletter & Stay Updated
